Newbury Pharmaceuticals AB (publ)

kr 1.61As of Sun 8 Nov 2026, 12:00 UTC
STO:NEWBRYHealthcare
Country Sweden
PE (Fwd) •••
TSR 5Y CAGR (32.21%)
Div yield —
ROE (73.51%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 1.30
PE TTM —
TSR TTM (28.44%)
Mkt cap kr 48.94M
ROIC (44.81%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 1.80
11.99%
(36.11%)
Hold 5|8|11|1|11
1Q26
2Q26
3Q26
4Q26
Earnings per sharekr
0.02
0.02
0.02
0.02
37.98%
35.71%
18.89%
19.20%
Revenuekr M
2.305
2.286
2.242
2.277
2.05%
1.60%
(5.17%)
(3.13%)
Peers (US$4.948M)
Cap (US$)
PE
7.846M
—
4.830M
0.121x
4.954M
—
Capital
TTM
5Y
10Y
Leveragex
0.457
0.231
0.191
EBIT/Intx
1.727
0.349
0.361
Own earn%
0.51
30.53
24.95
Sh yield%
33.58
28.15
28.85
Owners
Insiders/Inst%
6.07
80.43
Short interest%
4.43
SBC / revenue%
1.58
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
28–34
$1 testx
—
Incr. ROIC%
6